Selected Grants
A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab plus Nivolumab with or without Docetaxel versus Docetaxel Monotherapy in Second-Line Treatment of Participants with Metastatic Non-Squamous N
Clinical TrialPrincipal Investigator · Awarded by CatalYm GmbH · 2026 - 2031A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants Wi
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2025 - 2030External Relationships
- Aptitude health
- Cardinal Health, Inc.
- Charles River Associates
- Dava Oncology
- IDEOlogy Health
- Nuvation Bio Inc
- OncLive
- OncoHost
- Sermo
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.